• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Breast surgeons at the forefront: preserving lymph nodes for enhanced immunotherapy efficacy.

作者信息

Shi Zhiqiang, Zhao Qiuchen, Wang Yongsheng, Qiu Pengfei

机构信息

Breast Cancer Center, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan 250117, China.

Cancer Research UK Cambridge Centre and Department of Oncology, University of Cambridge, Cambridge, CB2 0XZ, UK.

出版信息

Cancer Biol Med. 2025 Jul 3;22(7):722-5. doi: 10.20892/j.issn.2095-3941.2025.0251.

DOI:10.20892/j.issn.2095-3941.2025.0251
PMID:40611581
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12302266/
Abstract
摘要

相似文献

1
Breast surgeons at the forefront: preserving lymph nodes for enhanced immunotherapy efficacy.前沿的乳腺外科医生：保留淋巴结以提高免疫治疗效果。
Cancer Biol Med. 2025 Jul 3;22(7):722-5. doi: 10.20892/j.issn.2095-3941.2025.0251.
2
Changing practice patterns in axillary management for patients with node-positive breast cancer towards increased use of sentinel lymph node biopsy-alone after neoadjuvant chemotherapy: results of a survey (MF17-01) among Turkish surgeons.新辅助化疗后，针对淋巴结阳性乳腺癌患者的腋窝处理模式发生变化，更多地采用仅前哨淋巴结活检：一项针对土耳其外科医生的调查（MF17 - 01）结果
Langenbecks Arch Surg. 2025 Jun 16;410(1):196. doi: 10.1007/s00423-025-03767-9.
3
Personalized axillary dissection: the number of excised lymph nodes of nodal-positive breast cancer patients has no significant impact on relapse-free and overall survival.个体化腋窝淋巴结清扫：淋巴结阳性乳腺癌患者切除的淋巴结数量对无复发生存率和总生存率无显著影响。
J Cancer Res Clin Oncol. 2017 Sep;143(9):1823-1831. doi: 10.1007/s00432-017-2425-3. Epub 2017 Apr 24.
4
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.接受新辅助化疗免疫治疗的早期乳腺癌患者乳腺MRI上的区域淋巴结变化
Breast Cancer Res Treat. 2025 Jan;209(1):147-159. doi: 10.1007/s10549-024-07481-w. Epub 2024 Sep 21.
5
An Open-Label Study of Subcutaneous CpG Oligodeoxynucleotide (PF03512676) in Combination with Trastuzumab in Patients with Metastatic HER2+ Breast Cancer.一项评价皮下注射 CpG 寡脱氧核苷酸（PF03512676）联合曲妥珠单抗治疗转移性 HER2+乳腺癌患者的开放性研究。
Cancer Control. 2024 Jan-Dec;31:10732748241250189. doi: 10.1177/10732748241250189.
6
A 3 M Evaluation Protocol for Examining Lymph Nodes in Cancer Patients: Multi-Modal, Multi-Omics, Multi-Stage Approach.一种用于检查癌症患者淋巴结的 3M 评估方案：多模态、多组学、多阶段方法。
Technol Cancer Res Treat. 2024 Jan-Dec;23:15330338241277389. doi: 10.1177/15330338241277389.
7
Cryogel-Based Dendritic Cell Immunotherapy for Post-Surgical Breast Cancer Treatment.
Adv Sci (Weinh). 2025 Jul 11:e03238. doi: 10.1002/advs.202503238.
8
Positron emission tomography (PET) and magnetic resonance imaging (MRI) for the assessment of axillary lymph node metastases in early breast cancer: systematic review and economic evaluation.正电子发射断层扫描（PET）和磁共振成像（MRI）在早期乳腺癌腋窝淋巴结转移评估中的应用：系统评价和经济评估。
Health Technol Assess. 2011 Jan;15(4):iii-iv, 1-134. doi: 10.3310/hta15040.
9
An Automatic Arrival Time Parametric Imaging Method for the Classification of Blood Perfusion Direction of Lymph Nodes in Contrast-Enhanced Ultrasound Videos.
Ultrasound Med Biol. 2025 Oct;51(10):1691-1700. doi: 10.1016/j.ultrasmedbio.2025.06.008. Epub 2025 Jul 19.
10
Seizing the fate of lymph nodes in immunotherapy: To preserve or not?抓住免疫治疗中淋巴结的命运：保留还是不保留？
Cancer Lett. 2024 Apr 28;588:216740. doi: 10.1016/j.canlet.2024.216740. Epub 2024 Feb 27.

本文引用的文献

1
Sentinel Lymph Node Biopsy vs No Axillary Surgery in Patients With Small Breast Cancer and Negative Results on Ultrasonography of Axillary Lymph Nodes: The SOUND Randomized Clinical Trial.前哨淋巴结活检与阴性超声腋窝淋巴结结果的小乳腺癌患者不进行腋窝手术的比较：SOUND 随机临床试验。
JAMA Oncol. 2023 Nov 1;9(11):1557-1564. doi: 10.1001/jamaoncol.2023.3759.
2
Dynamic CD8 T cell responses to cancer immunotherapy in human regional lymph nodes are disrupted in metastatic lymph nodes.在转移性淋巴结中，癌症免疫治疗在人体区域淋巴结中诱导的动态 CD8 T 细胞反应被打乱。
Cell. 2023 Mar 16;186(6):1127-1143.e18. doi: 10.1016/j.cell.2023.02.021.
3
Event-free Survival with Pembrolizumab in Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌无事件生存。
N Engl J Med. 2022 Feb 10;386(6):556-567. doi: 10.1056/NEJMoa2112651.
4
Tumor-draining lymph nodes: At the crossroads of metastasis and immunity.肿瘤引流淋巴结：转移和免疫的十字路口。
Sci Immunol. 2021 Sep 10;6(63):eabg3551. doi: 10.1126/sciimmunol.abg3551. Epub 2021 Sep 3.
5
First-line atezolizumab plus nab-paclitaxel for unresectable, locally advanced, or metastatic triple-negative breast cancer: IMpassion130 final overall survival analysis.一线阿替利珠单抗联合白蛋白紫杉醇治疗不可切除、局部晚期或转移性三阴性乳腺癌：IMpassion130 最终总生存分析。
Ann Oncol. 2021 Aug;32(8):983-993. doi: 10.1016/j.annonc.2021.05.355. Epub 2021 Jul 1.
6
Primary results from IMpassion131, a double-blind, placebo-controlled, randomised phase III trial of first-line paclitaxel with or without atezolizumab for unresectable locally advanced/metastatic triple-negative breast cancer.IMpassion131 研究是一项双盲、安慰剂对照、随机 III 期临床试验，旨在评估一线紫杉醇联合或不联合阿替利珠单抗治疗不可切除局部晚期/转移性三阴性乳腺癌的主要结果。
Ann Oncol. 2021 Aug;32(8):994-1004. doi: 10.1016/j.annonc.2021.05.801. Epub 2021 Jul 1.
7
Indications for individual internal mammary node irradiation.个别内乳淋巴结照射的适应症。
Lancet Oncol. 2021 Feb;22(2):e40. doi: 10.1016/S1470-2045(20)30739-7.
8
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial.帕博利珠单抗联合化疗对比安慰剂联合化疗用于治疗既往未经治疗的局部晚期不可切除或转移性三阴性乳腺癌（KEYNOTE-355）：一项随机、安慰剂对照、双盲、III 期临床研究。
Lancet. 2020 Dec 5;396(10265):1817-1828. doi: 10.1016/S0140-6736(20)32531-9.
9
Pembrolizumab for Early Triple-Negative Breast Cancer.帕博利珠单抗治疗早期三阴性乳腺癌。
N Engl J Med. 2020 Feb 27;382(9):810-821. doi: 10.1056/NEJMoa1910549.
10
Atezolizumab plus nab-paclitaxel as first-line treatment for unresectable, locally advanced or metastatic triple-negative breast cancer (IMpassion130): updated efficacy results from a randomised, double-blind, placebo-controlled, phase 3 trial.阿替利珠单抗联合白蛋白紫杉醇作为不可切除的局部晚期或转移性三阴性乳腺癌（IMpassion130）的一线治疗：一项随机、双盲、安慰剂对照、III 期临床试验的更新疗效结果。
Lancet Oncol. 2020 Jan;21(1):44-59. doi: 10.1016/S1470-2045(19)30689-8. Epub 2019 Nov 27.